Application of direct protein transduction of Stem Cell Factors to reprogram mouse and human somatic cells into pluripotent stem cells

应用干细胞因子直接蛋白转导将小鼠和人类体细胞重编程为多能干细胞

• 批准号: LP0989340
• 负责人: Prof Richard Boyd
• 金额: $ 44.4万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-04-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0989340
• 关键词: Application; direct; protein; transduction; Stem

This project aims to generate embryonic stem cell-like cells from human somatic cells, using direct protein transduction of defined factors, rather than through retroviral delivery. This will bring stem cell application closer to a therapeutic setting. The cells produced will be free from genetic modification and will yield products for patient-specific cell-based therapies that will be accepted by recipients without the need for immunosuppressant therapy. This development is expected to revolutionize the current approach to treating disease and injury, and is likely to result in the generation of highly marketable potent cell reprogramming therapeutics.

该项目旨在从人类体细胞中产生胚胎干细胞样细胞，使用直接蛋白质转导定义的因子，而不是通过逆转录病毒传递。这将使干细胞应用更接近于治疗环境。 所产生的细胞将不受遗传修饰，并将产生用于患者特异性细胞治疗的产品，这些产品将被接受者接受，而不需要免疫抑制剂治疗。 这一进展有望彻底改变目前治疗疾病和损伤的方法，并可能导致产生高度可销售的有效细胞重编程疗法。